Navamedic ASA (OSL:NAVA)

Market Cap	392.11M
Revenue (ttm)	542.59M
Net Income (ttm)	-10.95M
Shares Out	17.66M
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	26.59
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,914
Average Volume	6,028
Open	22.40
Previous Close	22.50
Day's Range	22.00 - 22.40
52-Week Range	17.10 - 35.90
Beta	0.39
RSI	55.15
Earnings Date	Apr 30, 2025

About Navamedic ASA

Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally. The company’s product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic and propioni...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 2002
• Employees: 42
• Stock Exchange: Oslo Børs
• Ticker Symbol: NAVA

Financial Performance

In 2024, Navamedic ASA's revenue was 531.44 million, an increase of 3.80% compared to the previous year's 512.00 million. Losses were -5.49 million, -59.92% less than in 2023.